Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M510317200 on November 30, 2005

J. Biol. Chem., Vol. 281, Issue 6, 3577-3585, February 10, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplmental Data
Right arrow All Versions of this Article:
281/6/3577    most recent
M510317200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lepesheva, G. I.
Right arrow Articles by Waterman, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lepesheva, G. I.
Right arrow Articles by Waterman, M. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

CYP51 from Trypanosoma cruzi

A PHYLA-SPECIFIC RESIDUE IN THE B' HELIX DEFINES SUBSTRATE PREFERENCES OF STEROL 14{alpha}-DEMETHYLASE*Formula

Galina I. Lepesheva{ddagger}1, Natalia G. Zaitseva{ddagger}, W. David Nes§, Wenxu Zhou§, Miharu Arase{ddagger}, Jialin Liu§, George C. Hill, and Michael R. Waterman{ddagger}

From the Departments of {ddagger}Biochemistry and Microbiology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 and the §Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas 79409

A potential drug target for treatment of Chagas disease, sterol 14{alpha}-demethylase from Trypanosoma cruzi (TCCYP51), was found to be catalytically closely related to animal/fungi-like CYP51. Contrary to the ortholog from Trypanosoma brucei (TB), which like plant CYP51 requires C4-monomethylated sterol substrates, TCCYP51 prefers C4-dimethylsterols. Sixty-six CYP51 sequences are known from bacteria to human, their sequence homology ranging from ~25% between phyla to ~80% within a phylum. TC versus TB is the first example of two organisms from the same phylum, in which CYP51s (83% amino acid identity) have such profound differences in substrate specificity. Substitution of animal/fungi-like Ile105 in the B' helix to Phe, the residue found in this position in all plant and the other six CYP51 sequences from Trypanosomatidae, dramatically alters substrate preferences of TCCYP51, converting it into a more plant-like enzyme. The rates of 14{alpha}-demethylation of obtusifoliol and its 24-demethyl analog 4{alpha}-,4{alpha}-dimethylcholesta-8,24-dien-3beta-ol(norlanosterol) increase 60- and 150-fold, respectively. Turnover of the three 4,4-dimethylated sterol substrates is reduced ~3.5-fold. These catalytic properties correlate with the sterol binding parameters, suggesting that Phe in this position provides necessary interactions with C4-monomethylated substrates, which Ile cannot. The CYP51 substrate preferences imply differences in the post-squalene portion of sterol biosynthesis in TC and TB. The phyla-specific residue can be used to predict preferred substrates of new CYP51 sequences and subsequently for the development of new artificial substrate analogs, which might serve as highly specific inhibitors able to kill human parasites.


Received for publication, September 20, 2005 , and in revised form, November 29, 2005.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AY856083 [GenBank] .

* This work was supported by National Institutes of Health Grants GM067871 and ES00267-32 (to M. R. W.) and GM63477 (to W. D. N.), American Heart Association Grant 0535121N (to G. I. L.), and Welch Foundation Grant D-1276 to W. D. N.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental material.

1 To whom correspondence should be addressed: Dept. of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232-0146. Tel.: 615-343-1373; Fax: 615-322-4349; E-mail: galina.i.lepesheva{at}vanderbilt.edu.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
A. N. Eddine, J. P. von Kries, M. V. Podust, T. Warrier, S. H. E. Kaufmann, and L. M. Podust
X-ray Structure of 4,4'-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14{alpha}-Demethylase (CYP51)
J. Biol. Chem., May 30, 2008; 283(22): 15152 - 15159.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
L. M. Podust, J. P. von Kries, A. N. Eddine, Y. Kim, L. V. Yermalitskaya, R. Kuehne, H. Ouellet, T. Warrier, M. Altekoster, J.-S. Lee, et al.
Small-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray Crystallography
Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3915 - 3923.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement